Multiplexed, image-based pooled screens in primary cells and tissues with PerturbView

Affiliations
  • 1Genentech Research and Early Development, Genentech, Inc., South San Francisco, CA, USA.
  • 2Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
  • 3Faculty of Environment and Information Studies, Keio University, Tokyo, Japan.
  • 4Bioinformatics Department, ProCogia, Toronto, Ontario, Canada.
  • 5Genentech Research and Early Development, Genentech, Inc., South San Francisco, CA, USA. regeva@gene.com.
  • 6Genentech Research and Early Development, Genentech, Inc., South San Francisco, CA, USA. lubecke@gene.com.

|

Abstract

Optical pooled screening (OPS) is a scalable method for linking image-based phenotypes with cellular perturbations. However, it has thus far been restricted to relatively low-plex phenotypic readouts in cancer cell lines in culture due to limitations associated with in situ sequencing of perturbation barcodes. Here, we develop PerturbView, an OPS technology that leverages in vitro transcription to amplify barcodes before in situ sequencing, enabling screens with highly multiplexed phenotypic readouts across diverse systems, including primary cells and tissues. We demonstrate PerturbView in induced pluripotent stem cell-derived neurons, primary immune cells and tumor tissue sections from animal models. In a screen of immune signaling pathways in primary bone marrow-derived macrophages, PerturbView uncovered both known and novel regulators of NF-κB signaling. Furthermore, we combine PerturbView with spatial transcriptomics in tissue sections from a mouse xenograft model, paving the way to in situ screens with rich optical and transcriptomic phenotypes. PerturbView broadens the scope of OPS to a wide range of models and applications.